3UI7

Discovery of orally active pyrazoloquinoline as a potent PDE10 inhibitor for the management of schizophrenia

• PDB DOI: https://doi.org/10.2210/pdb3UI7/pdb

• Classification: HYDROLASE/HYDROLASE INHIBITOR
• Organism(s): Homo sapiens
• Expression System: Spodoptera frugiperda
• Mutation(s): No 


• Deposited: 2011-11-04 Released: 2011-12-21 
• Deposition Author(s): Yang, S., Smotryski, J., Mcelroy, W., Ho, G., Tulshian, D., Greenlee, W.J., Hodgson, R., Xiao, L., Hruza, A.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.28 Å
• R-Value Free: 
  0.240 (Depositor), 0.270 (DCC) 
• R-Value Work: 
  0.195 (Depositor), 0.220 (DCC) 
• R-Value Observed: 
  0.197 (Depositor) 

Literature

Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia.

Yang, S.W., Smotryski, J., McElroy, W.T., Tan, Z., Ho, G., Tulshian, D., Greenlee, W.J., Guzzi, M., Zhang, X., Mullins, D., Xiao, L., Hruza, A., Chan, T.M., Rindgen, D., Bleickardt, C., Hodgson, R.

(2012) Bioorg Med Chem Lett 22: 235-239

• PubMed: 22142545 
• DOI: https://doi.org/10.1016/j.bmcl.2011.11.023
• Primary Citation of Related Structures:  
  3UI7


• PubMed Abstract: 
  

  A series of pyrazoloquinoline analogs have been synthesized and shown to bind to PDE10 with high affinity. From the SAR study and our lead optimization efforts, compounds 16 and 27 were found to possess potent oral antipsychotic activity in the MK-801 induced hyperactive rat model.

---

Organizational Affiliation: 

Department of Medicinal Chemistry, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, NJ 07033, United States. [e-mail]

Biological Assembly 1  

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors and generated by PISA (software)

Biological Assembly 2  

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 2 assigned by authors and generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 78.02 kDa 
• Atom Count: 5,275 
• Modelled Residue Count: 630 
• Deposited Residue Count: 666 
• Unique protein chains: 1

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	A, B	333	Homo sapiens	Mutation(s): 0  Gene Names: PDE10A EC: 3.1.4.17 (PDB Primary Data), 3.1.4.35 (PDB Primary Data)
UniProt & NIH Common Fund Data Resources
Find proteins for Q9Y233 (Homo sapiens) Explore Q9Y233  Go to UniProtKB:  Q9Y233
PHAROS:  Q9Y233 GTEx:  ENSG00000112541

Small Molecules

Ligands 3 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
C1L	C [auth A], F [auth B]	6-methoxy-3,8-dimethyl-4-(morpholin-4-ylmethyl)-1H-pyrazolo[3,4-b]quinoline C18 H22 N4 O2 UBGXXNXAPLUDQK-UHFFFAOYSA-N
ZN	E [auth A], H [auth B]	ZINC ION Zn PTFCDOFLOPIGGS-UHFFFAOYSA-N
MG	D [auth A], G [auth B]	MAGNESIUM ION Mg JLVVSXFLKOJNIY-UHFFFAOYSA-N

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.28 Å
• R-Value Free:  0.240 (Depositor), 0.270 (DCC) 
• R-Value Work:  0.195 (Depositor), 0.220 (DCC) 
• R-Value Observed: 0.197 (Depositor) 

Space Group: P 2₁ 2₁ 2₁

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 49.539	α = 90
b = 81.611	β = 90
c = 158.577	γ = 90

Software Package:

Software Name	Purpose
BUSTER	refinement
autoPROC	data scaling
XDS	data reduction
SCALA	data scaling

Structure Validation

Entry History 

Deposition Data

• Released Date: 2011-12-21 
Deposition Author(s): Yang, S., Smotryski, J., Mcelroy, W., Ho, G., Tulshian, D., Greenlee, W.J., Hodgson, R., Xiao, L., Hruza, A.

Revision History  

• Version 1.0: 2011-12-21
  Type: Initial release
  
• Version 1.1: 2012-01-11
  Changes: Database references
• Version 1.2: 2024-02-28
  Changes: Data collection, Database references, Derived calculations, Refinement description